Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.1 CHF | -1.95% | -13.29% | -0.88% |
Apr. 23 | DOCMORRIS : Deutsche Bank remains its Buy rating | ZD |
Apr. 19 | DOCMORRIS : Hauck & Aufhauser gives a Buy rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.08% | 1.03B | B- | ||
-34.16% | 14.83B | B- | ||
-22.76% | 12.04B | B | ||
-24.53% | 6.52B | B | ||
+14.96% | 6.44B | C | ||
-9.27% | 6.15B | C+ | ||
-2.48% | 4.63B | D- | ||
+60.00% | 4.62B | C | ||
-8.10% | 3.93B | B | ||
-11.16% | 3.49B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROSE Stock
- Ratings DocMorris AG